Precision Infrastructure
Advanced Manufacturing & Scientific Discovery
Hahobal redefines oncology therapeutics through an asset-light model. By orchestrating a global network of elite, WHO-GMP certified Contract Manufacturing Organizations (CMOs), we focus on what matters most: delivering life-saving science at scale without the constraints of legacy infrastructure.
Manufacturing Excellence
Automated Sterile Formulation
We collaborate exclusively with top-tier CMOs equipped with closed-loop robotic systems and automated sterile formulation lines. This ensures zero-contamination environments for our highly sensitive oncology portfolio across partner facilities.
Batch Reliability
"Strategic outsourcing is the catalyst for uncompromised patient safety and rapid, global scalability."
Air Quality Control
Our partner facilities are strictly mandated to maintain Class 100 HEPA filtration and ISO 5 standards across all critical processing zones.
API Synthesis
Leveraging specialized global alliances to source the highest purity active pharmaceutical ingredients, eliminating supply chain bottlenecks.
Cold Chain Logistics
End-to-end, IoT-monitored -80°C storage managed by elite logistics partners, ensuring molecule integrity directly from the CMO to the clinic.
Rigorous Quality Assurance
We may not own the facilities, but we own the quality. Our independent QA framework dictates absolute compliance, employing real-time digital auditing and batch-by-batch validation for every outsourced product.
- Real-time Analytical MonitoringMandatory third-party HPLC and Mass Spectrometry validation for every outsourced batch.
- LIMS IntegrationReal-time data synchronization between our headquarters and partner CMOs for total operational transparency.
Future Research Priorities
T-Cell Engineering
Co-developing advanced chimeric antigen receptor (CAR) T-cell therapies with leading clinical research organizations.
Precision Biomarkers
Funding third-party diagnostic pioneers to predict patient response to targeted biological agents effectively.
Nano-drug Carriers
Partnering with specialized nanomaterial labs to optimize lipid nanoparticle delivery systems for solid tumor penetration.
Global Expansion Roadmap
Strategically scaling our footprint to ensure high-efficacy oncology care is accessible across emerging and established markets.
2027-2028
Sri Lanka
South Asia
2027-2028
Singapore
Southeast Asia
2029-2030
United Arab Emirates
Middle East
2031
Europe
European Network